Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Original languageEnglish (US)
Pages (from-to)189-197
Number of pages9
JournalTherapeutic Advances in Gastroenterology
Volume5
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Vasopressin Receptors
Hyponatremia
Ascites
Fibrosis
End Stage Liver Disease
Hepatic Encephalopathy
Arginine Vasopressin
Liver Transplantation
Liver Diseases
Hemodynamics
Sodium
Antidiuretic Hormone Receptor Antagonists
Safety
Mortality
Serum
Pharmaceutical Preparations

Keywords

  • ascites
  • cirrhosis
  • hepatorenal syndrome
  • hyponatremia
  • lixivaptan
  • portal hypertension
  • satavaptan
  • tolvaptan
  • vasopressin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{5507ded01ec14d4e8f61be85ff57d8e8,
title = "Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia",
abstract = "Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.",
keywords = "ascites, cirrhosis, hepatorenal syndrome, hyponatremia, lixivaptan, portal hypertension, satavaptan, tolvaptan, vasopressin",
author = "Habib, {Shahid -} and Boyer, {Thomas D}",
year = "2012",
month = "5",
doi = "10.1177/1756283X12437357",
language = "English (US)",
volume = "5",
pages = "189--197",
journal = "Therapeutic Advances in Gastroenterology",
issn = "1756-283X",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia

AU - Habib, Shahid -

AU - Boyer, Thomas D

PY - 2012/5

Y1 - 2012/5

N2 - Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

AB - Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

KW - ascites

KW - cirrhosis

KW - hepatorenal syndrome

KW - hyponatremia

KW - lixivaptan

KW - portal hypertension

KW - satavaptan

KW - tolvaptan

KW - vasopressin

UR - http://www.scopus.com/inward/record.url?scp=84860508849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860508849&partnerID=8YFLogxK

U2 - 10.1177/1756283X12437357

DO - 10.1177/1756283X12437357

M3 - Article

C2 - 22570679

AN - SCOPUS:84860508849

VL - 5

SP - 189

EP - 197

JO - Therapeutic Advances in Gastroenterology

JF - Therapeutic Advances in Gastroenterology

SN - 1756-283X

IS - 3

ER -